Epstein-Barr virus (EBV). IV. Studies on experimental inactivated vaccine against human EBV infection.
It is well established that EBV-immunogen successfully invoke a strong neutralizing anti-EBV response in experimental animals. The authors report here the successful production of an EBV-immunogen prepared with whole disrupted productive cells of 2 MEBV cell line and with whole virus inactivated with ethylenimine (EI) which produce neutralizing anti-EBV response in experimental animals (calves, sheep, rabbits and SPF chickens).
Pătraşcu
I V
IV
Stefan S. Nicolau Institute of Virology, Bucharest, Romania.
Tache
M
M
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D002051:Burkitt Lymphoma / Q000517:prevention & control*; D002417:Cattle; D002645:Chickens; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007244:Infectious Mononucleosis / Q000517:prevention & control*; D009500:Neutralization Tests; D011817:Rabbits; D012756:Sheep; D014412:Tumor Virus Infections / Q000517:prevention & control*; D014613:Vaccines, Attenuated / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines